“LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for ...
Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of ...
PRINCETON, N.J., Dec. 1, 2023 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...
PRINCETON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the launch of a new tool to help healthcare providers (HCPs) ...
Study Supported by $2.6 Million FDA Orphan Products Development Grant "We are pleased with these recent study results and that the FDA is continuing to financially support the HyBryte™ program, giving ...
Citius Oncology launches US FDA approved Lymphir, a novel cancer immunotherapy for cutaneous T-cell lymphoma: Cranford, New Jersey Wednesday, December 3, 2025, 16:00 Hrs [IST] Cit ...
On Monday, Soligenix, Inc. (NASDAQ:SNGX) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). The ...
Late-stage biopharmaceutical company Soligenix, Inc. SNGX focuses on developing treatments for rare and underserved diseases. Primarily, the firm specializes in providing groundbreaking treatments for ...
Stocktwits on MSN
Citius Oncology Launches Lymphir In US For Skin Cancer
Citius Oncology (CTOR) said on Monday it has launched Lymphir, a newly approved cancer immunotherapy for adults with relapsed ...
Please provide your email address to receive an email when new articles are posted on . HyBryte is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. Three of ...
JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback